MedImmune LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children
Phase 3
Completed
- Conditions
- Respiratory Tract Infections
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2200
- Registration Number
- NCT00192205
- Locations
- ๐ฎ๐ฑ
Schneider Children's Medical Center of Israel, Petah-Tikva, Israel
๐ช๐ธHospital de Txagorritxu, Vitoria, Spain
Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)
Phase 2
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00192387
- Locations
- ๐บ๐ธ
Monroe Clinic, Monroe, Wisconsin, United States
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00192231
- Locations
- ๐ฆ๐บ
Austin & Repatriation Medical Centre, Heidelburg, Victoria, Australia
Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 2400
- Registration Number
- NCT00192426
Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Prophylaxis
- Interventions
- Biological: MotavizumabOther: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00192504
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00192348
- Locations
- ๐ซ๐ฎ
University of Tampere, Tampere, Finland
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: FluMistOther: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00192127
- Locations
- ๐บ๐ธ
SFBC International, Inc, Miami, Florida, United States
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
Phase 2
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 240
- Registration Number
- NCT00192153
- Locations
- ๐บ๐ธ
West Coast Medical Associates, New Port Richey, Florida, United States
๐บ๐ธUniversity of VA Health Sciences Center, Charlottesville, Virginia, United States
Long-Term Follow-Up Study of Psoriasis Patients
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00131066
- Locations
- ๐บ๐ธ
Dermatology Research Clinic, Little Rock, Arkansas, United States
๐บ๐ธCherry Creek Dermatology, Denver, Colorado, United States
๐บ๐ธAtlanta Dermatology, Vein & Research Center, LLC, Alpharetta, Georgia, United States
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Phase 3
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: palivizumabBiological: motavizumab (MEDI-524)
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 6635
- Registration Number
- NCT00129766
- Locations
- ๐บ๐ธ
University Of Alabama At Birmingham, Birmingham, Alabama, United States
๐บ๐ธAlabama Neonatal Medicine OC, Pike Road, Alabama, United States
๐บ๐ธMaricopa Medical Center, Phoenix, Arizona, United States